Want to see PRLD full AI Analyst Report?
PRLD Stock Chart & Stats
$6.34
$0.75(19.28%)
At close: 4:00 PM EDT
$6.34
$0.75(19.28%)
Day’s Range― - ―
52-Week Range$1.17 - $6.83
Previous Close$4.6
Volume1.86M
Average Volume (3M)468.40K
Market Cap
$281.71M
Enterprise Value$390.30M
Total Cash (Recent Filing)$151.76M
Total Debt (Recent Filing)$17.65M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Nov 05, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding65,075,350
10 Day Avg. Volume416,988
30 Day Avg. Volume468,401
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)3.25
Price to Sales (P/S)18.38
P/FCF Ratio-3.96
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue17.41
Enterprise Value/Gross Profit17.71
Enterprise Value/Ebitda-6.63
Forecast
1Y Price Target
$10.00Price Target Upside57.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$39.23M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling And Gross MarginRevenue has expanded materially while reported gross margin remains very high, indicating stronger commercial activity and favorable economics on existing revenue. If growth continues, this combination could provide a stronger base for funding pipeline development and eventually improving operating leverage.
Conservative LeverageModest debt relative to equity gives Prelude more financial flexibility than a highly leveraged development-stage company. Stable borrowing levels and a larger capital base can help the company continue advancing oncology programs while reducing pressure from near-term debt obligations.
Pipeline AdvancementFDA clearance moves PRT13722 into human clinical development and creates a tangible next step for Prelude’s precision-oncology platform. The first-in-human study may generate safety, pharmacology, and activity data that can validate the asset and support future development or collaboration.
Bears Say
Persistent Operating LossesPrelude remains deeply unprofitable, with losses several times larger than reported revenue. Continued operating deficits limit internal funding capacity and mean that revenue growth has not yet translated into a self-sustaining business, leaving profitability dependent on future execution and financing.
Negative Cash GenerationAlthough cash burn has improved from 2024 and 2025, Prelude still consumes substantial cash to operate and develop its pipeline. Persistent negative free cash flow increases dependence on available funding and could constrain program advancement if financing conditions or partnering support become less favorable.
Early-stage Clinical RiskThe pipeline’s progress remains exposed to the uncertainty of early clinical development, because PRT13722 has not yet demonstrated safety, tolerability, or antitumor activity in patients. Results from the Phase 1 study will therefore be important to validating the program’s commercial potential.
Prelude Therapeutics News
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $1.17 and its highest was $6.83 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Prelude Therapeutics’s market cap is $281.71M.
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 15 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on Aug 19, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.197 by $0.057.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is 0.01.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 65,075,350 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.197. Following the earnings report the stock price went up 0.522%.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Currently, no hedge funds are holding shares in PRLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prelude Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (57.73% Upside)
$10.00 (57.73% Upside)
Blogger Sentiment
Bullish
PRLD Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 6.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 7.9%
Last 30 Days ▲ 7.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
173.64%
12-Months-Change
Fundamentals
Return on Equity
-75.35%
Trailing 12-Months
Asset Growth
64.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prelude Therapeutics
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
PRLD Stock 12 Month Forecast
Average Price Target
$10.00
▲(57.73% Upside)
Technical Analysis
Ownership Overview
30.04% Insiders
1.95% Mutual Funds
48.93% Other Institutional Investors
14.90% Public Companies and
Individual Investors